The estimated Net Worth of Jonathan Lewis is at least $677 Tysiąc dollars as of 6 January 2014. Jonathan Lewis owns over 268,653 units of Alaunos Therapeutics Inc stock worth over $677,213 and over the last 18 years Jonathan sold ZIOP stock worth over $0.
Jonathan has made over 1 trades of the Alaunos Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Jonathan exercised 268,653 units of ZIOP stock worth $21,492 on 6 January 2014.
The largest trade Jonathan's ever made was exercising 268,653 units of Alaunos Therapeutics Inc stock on 6 January 2014 worth over $21,492. On average, Jonathan trades about 11,194 units every 0 days since 2006. As of 6 January 2014 Jonathan still owns at least 778,406 units of Alaunos Therapeutics Inc stock.
You can see the complete history of Jonathan Lewis stock trades at the bottom of the page.
Jonathan's mailing address filed with the SEC is C/O DELCATH SYSTEMS, INC., 1100 SUMMER ST, STAMFORD, CT, 06905.
Over the last 18 years, insiders at Alaunos Therapeutics Inc have traded over $2,792,771 worth of Alaunos Therapeutics Inc stock and bought 7,941,160 units worth $39,823,909 . The most active insiders traders include Randal J Kirk, Randal Jintrexon Corp Kirk oraz Lindsay A Md Rosenwald. On average, Alaunos Therapeutics Inc executives and independent directors trade stock every 72 days with the average trade being worth of $152,086. The most recent stock trade was executed by Groot Eleanor De on 22 December 2021, trading 20,132 units of ZIOP stock currently worth $25,568.
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.
Alaunos Therapeutics Inc executives and other stock owners filed with the SEC include: